Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EVIO, Inc. (EVIO)
Henderson, NV, US
EVIO, Inc., along with its affiliates, provides specialized analytical testing and expert advisory services to the cannabis industry throughout the United States. The company's consulting expertise spans strategic guidance, product formulation assistance, and comprehensive support for licensing and regulatory compliance. Furthermore, EVIO conducts a full range of laboratory analyses, including cannabinoid potency assessment, terpene profiling, pesticide screening, residual solvent detection, visual inspections, and biological contaminant testing. The firm maintains its headquarters in Henderson, Nevada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +4,900.00% | +4,900.00% | -50.00% | +4,900.00% | +4,900.00% | +4,900.00% | -97.83% | -99.94% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-32.7% Q4'22: -53.9% (vs Q4'19)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★ Q4'22: +100.0% (vs Q4'19)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.1% Q4'22: +59.2% (vs Q4'19)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.9% ★ Q4'22: +30.9% (vs Q4'19)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'22: -15.2% (vs Q4'19)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'22: +53,707.6% (vs Q4'19)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×10.89× Q4'22: 9.08× (vs Q4'19)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2018 actual |
Sep 2019 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
|---|---|---|---|---|---|
| Revenue |
3.37M
est: 3.81M (-11.7%)
|
3.79M
est: 6.48M (-41.5%)
|
3.81M
est.
|
6.48M
est.
|
9.59M
est.
|
| EBITDA |
-7.45M
est: -1.28M (-482.8%)
|
-5.86M
est: -2.17M (-169.5%)
|
-1.28M
est.
|
-2.17M
est.
|
-3.22M
est.
|
| EBIT |
-8.18M
est: -1.97M (-314.6%)
|
-7.33M
est: -3.35M (-118.4%)
|
-1.97M
est.
|
-3.35M
est.
|
-4.96M
est.
|
| Net Income |
-11.63M
|
-20.67M
|
-401.38M
est.
|
-256.88M
est.
|
-32.11M
est.
|
| SGA |
7.50M
est: 6.08M (+23.3%)
|
6.16M
est: 10.34M (-40.5%)
|
6.09M
est.
|
10.34M
est.
|
15.30M
est.
|
| EPS |
-0.70
|
-0.77
|
-0.25
est.
|
-0.16
est.
|
-0.02
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Markets Division of Spear, Leeds & Kellogg | 268.2K | 11.00% | — | — | — | — | BD | USA | 2000-02-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-01-31 | Waldrop William | Director / Officer / 10% Owner | A-Award | A | Common Stock | 3,029,007 | 0.07 | 216.6K | 4,394,007 | — | ↗ |
| 2020-01-31 | Smith Anthony R. | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,820,881 | 0.07 | 130.2K | 1,830,881 | — | ↗ |
| 2020-01-31 | GLAUSER LORI JEAN | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,503,650 | 0.07 | 179.0K | 3,947,017 | — | ↗ |
| 2019-06-06 | GLAUSER LORI JEAN | — | P-Purchase | A | Common Stock | 7,000 | 0.31 | 2.2K | 1,443,367 | — | ↗ |
| 2017-11-10 | GLAUSER LORI JEAN | — | P-Purchase | A | Common Stock | 6,000 | 0.55 | 3.3K | 1,427,667 | — | ↗ |
| 2017-11-09 | GLAUSER LORI JEAN | — | P-Purchase | A | Common Stock | 10,000 | 0.54 | 5.4K | 1,421,667 | — | ↗ |
| 2017-09-08 | GLAUSER LORI JEAN | — | P-Purchase | A | Common Stock | 5,000 | 1.05 | 5.3K | 1,411,667 | — | ↗ |
| 2017-09-07 | GLAUSER LORI JEAN | — | P-Purchase | A | Common Stock | 8,667 | 1.06 | 9.2K | 1,406,667 | — | ↗ |
| 2016-11-02 | Waldrop William | — | S-Sale | D | Common Stock | 3,000,000 | 0.04 | 129.0K | 136,500,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheryl Kramp | Director of Marketing | — | — |
| Lori Jean Glauser | Pres, Chief Operating Officer & Director | — | female |
| William H. Waldrop | Chief Executive Officer & Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EVIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
